External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology IMS 2025
Roche and Genentech at

IMS 2025

September 17 - September 20
Toronto, Canada / Virtual (Hybrid)
events.jspargo.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:10 PM
Duration 10mins Room 701
Cevostamab plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM): Phase I dose expansion results from the CAMMA 1 study
Mian HS, Riley CH, Popat R, Grosicki S, Lavi N, Harrison S, Mihalyova J, Kim K, Trudel S, Szarejko M, Sandhu I, Paris L, Mishra A, Tyagi T, Chebon S, Sewpaul P, Richardson L, Nielsen T, Spencer A
Haematology | Hematologic Diseases

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.